Literature DB >> 26430088

Risk Stratification for Rejection and Infection after Kidney Transplantation.

Pietro E Cippà1, Marc Schiesser2, Henrik Ekberg3, Teun van Gelder4, Nicolas J Mueller5, Claude A Cao6, Thomas Fehr7, Corrado Bernasconi8.   

Abstract

BACKGROUND AND OBJECTIVES: Definition of individual risk profile is the first step to implement strategies to keep the delicate balance between under- and overimmunosuppression after kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used data from the Efficacy Limiting Toxicity Elimination Symphony Study (1190 patients between 2002 and 2004) to model risk of rejection and infection in the first year after kidney transplantation. External validation was performed in a study population from the Fixed-Dose Concentration-Controlled Trial (630 patients between 2003 and 2006).
RESULTS: Despite different temporal dynamics, rejections and severe infections had similar overall incidences in the first year after transplantation (23.4% and 25.5%, respectively), and infections were the principal cause of death (43.2% of all deaths). Recipient older age, deceased donor, higher number of HLA mismatches, and high risk for cytomegalovirus disease were associated with infection; deceased donor, higher number of HLA mismatches, and immunosuppressive therapy including cyclosporin A (compared with tacrolimus), with rejection. These factors were integrated into a two-dimensional risk stratification model, which defined four risk groups: low risk for infection and rejection (30.8%), isolated risk for rejection (36.1%), isolated risk for infection (7.0%), and high risk for infection and rejection (26.1%). In internal validation, this model significantly discriminated the subgroups in terms of composite end point (low risk for infection/rejection, 24.4%; isolated risk for rejection and isolated risk for infection, 31.3%; high risk for infection/rejection, 54.4%; P<0.001), rejection episodes (isolated risk for infection and low risk for infection/rejection, 13.0%; isolated risk for rejection and high risk for infection/rejection, 24.2%; P=0.001), and infection episodes (low risk for infection/rejection and isolated risk for rejection, 12.0%; isolated risk for infection and high risk for infection/rejection, 37.6%; P<0.001). External validation confirmed the applicability of the model to an independent cohort.
CONCLUSIONS: We propose a two-dimensional risk stratification model able to disentangle the individual risk for rejection and infection in the first year after kidney transplantation. This concept can be applied to implement a personalized immunosuppressive and antimicrobial treatment approach.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  cause of death; cyclosporin; death; humans; immunosuppression; kidney transplantation; tacrolimus; transplant infectious disease; transplant outcomes; transplant recipients

Mesh:

Substances:

Year:  2015        PMID: 26430088      PMCID: PMC4670759          DOI: 10.2215/CJN.01790215

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

Review 1.  Strategies to improve long-term outcomes after renal transplantation.

Authors:  Manuel Pascual; Tom Theruvath; Tatsuo Kawai; Nina Tolkoff-Rubin; A Benedict Cosimi
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

2.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

3.  The global role of kidney transplantation.

Authors:  Guillermo Garcia Garcia; Paul Harden; Jeremy Chapman
Journal:  Lancet       Date:  2012-03-08       Impact factor: 79.321

Review 4.  Diagnosis and prevention of chronic kidney allograft loss.

Authors:  Brian J Nankivell; Dirk R J Kuypers
Journal:  Lancet       Date:  2011-10-15       Impact factor: 79.321

Review 5.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.

Authors:  Adnan Sharif; Shazia Shabir; Sourabh Chand; Paul Cockwell; Simon Ball; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2011-09-23       Impact factor: 10.121

Review 6.  Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?

Authors:  H U Meier-Kriesche; B Kaplan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Common infections in kidney transplant recipients.

Authors:  Shamila Karuthu; Emily A Blumberg
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-13       Impact factor: 8.237

8.  Death within the first year after kidney transplantation--an observational cohort study.

Authors:  Daniela Farrugia; James Cheshire; Irena Begaj; Sajan Khosla; Daniel Ray; Adnan Sharif
Journal:  Transpl Int       Date:  2013-11-14       Impact factor: 3.782

9.  Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort.

Authors:  Michael T Koller; Christian van Delden; Nicolas J Müller; Philippe Baumann; Christian Lovis; Hans-Peter Marti; Thomas Fehr; Isabelle Binet; Sabina De Geest; Heiner C Bucher; Pascal Meylan; Manuel Pascual; Jürg Steiger
Journal:  Eur J Epidemiol       Date:  2013-04-02       Impact factor: 8.082

10.  Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.

Authors:  Hélio Tedesco Silva; Harold C Yang; Herwig-Ulf Meier-Kriesche; Richard Croy; John Holman; William E Fitzsimmons; M Roy First
Journal:  Transplantation       Date:  2014-03-27       Impact factor: 4.939

View more
  23 in total

1.  Antibiotic therapy in case of positive cultures of kidney transplant preservation fluid: a nationwide survey of prescribing practices.

Authors:  N Le Berre; M Ladrière; A Corbel; T Remen; L Durin; L Frimat; N Thilly; C Pulcini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-04       Impact factor: 3.267

2.  Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury.

Authors:  Todd A Miano; Judd D Flesch; Rui Feng; Caitlin M Forker; Melanie Brown; Michelle Oyster; Laurel Kalman; Melanie Rushefski; Edward Cantu; Mary Porteus; Wei Yang; A Russel Localio; Joshua M Diamond; Jason D Christie; Michael G S Shashaty
Journal:  Clin Pharmacol Ther       Date:  2019-10-20       Impact factor: 6.875

3.  Induction Therapy and Therapeutic Antibodies.

Authors:  Andriana Nikolova; Jignesh K Patel
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Oral/oesophageal candidiasis is a risk factor for severe infection after kidney transplantation.

Authors:  Tetsuya Abe; Kenta Futamura; Norihiko Goto; Kiyomi Ohara; Taiki Ogasa; Toshihide Tomosugi; Manabu Okada; Takahisa Hiramitsu; Shunji Narumi; Yoshihiko Watarai
Journal:  Nephrology (Carlton)       Date:  2021-08-21       Impact factor: 2.358

5.  T cell senescence and impaired CMV-specific response are associated with infection risk in kidney transplant recipients.

Authors:  Harry Pickering; Joanna Schaenman; Maura Rossetti; Richard Ahn; Gemalene Sunga; Emily C Liang; Suphamai Bunnapradist; Elaine F Reed
Journal:  Hum Immunol       Date:  2022-02-18       Impact factor: 2.211

6.  Single-center analysis of infectious complications in older adults during the first year after kidney transplantation.

Authors:  Marion Hemmersbach-Miller; Barbara D Alexander; Debra L Sudan; Carl Pieper; Kenneth E Schmader
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-23       Impact factor: 3.267

Review 7.  Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know.

Authors:  Giovanni Piotti; Elena Cremaschi; Umberto Maggiore
Journal:  J Nephrol       Date:  2016-05-20       Impact factor: 3.902

8.  Role of serum CXCL9 and CXCL13 in predicting infection after kidney transplant: A STROBE study.

Authors:  Lin Yan; Ya-Mei Li; Yi Li; Yang-Juan Bai; Zheng-Li Wan; Ji-Wen Fan; Li-Mei Luo; Lan-Lan Wang; Yun-Ying Shi
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

9.  Long-Term Outcomes among Kidney Transplant Recipients and after Graft Failure: A Single-Center Cohort Study in Brazil.

Authors:  Paula Rebello Bicalho; Lúcio R Requião-Moura; Érika Ferraz Arruda; Rogerio Chinen; Luciana Mello; Ana Paula F Bertocchi; Erika Lamkowski Naka; Eduardo José Tonato; Alvaro Pacheco-Silva
Journal:  Biomed Res Int       Date:  2019-04-02       Impact factor: 3.411

Review 10.  Immune checkpoint inhibitors to treat cutaneous malignancies.

Authors:  Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-24       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.